Peptidream Inc. (JP:4587)
:4587
Want to see JP:4587 full AI Analyst Report?
4587 Stock Chart & Stats
¥1669.00
-¥31.00(-1.24%)
At close: 4:00 PM EST
¥1669.00
-¥31.00(-1.24%)
Day’s Range― - ―
52-Week Range¥985.10 - ¥1,818.50
Previous CloseN/A
Volume553.80K
Average Volume (3M)1.01M
Market Cap
¥130.02B
Enterprise Value¥133.03B
Total Cash (Recent Filing)¥25.55B
Total Debt (Recent Filing)¥16.34B
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 12, 2026EPS Estimate
-3.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.64
Shares Outstanding130,010,400
10 Day Avg. Volume808,920
30 Day Avg. Volume1,013,253
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,600.00Price Target Upside-4.13% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)72.03
Revenue Forecast (FY)¥40.02B
Bulls Say, Bears Say
Bulls Say
Platform & Clinical PipelinePeptiDream's PDPS-driven pipeline produced six clinical entries in 2025 (13 total), showing durable funnel conversion from discovery to clinic. A deepening clinical slate raises the cadence of milestone triggers and royalty optionality, shifting the firm toward recurring development economics and de‑risking any single program over the medium term.
Strong Net-Cash BufferA JPY 28.6B cash balance and net‑cash status provide multi-quarter runway to fund higher R&D and capital projects without immediate equity raises. This balance‑sheet strength supports sustained investment in clinical programs and manufacturing expansion, giving management flexibility to time partnerships and preserve valuation optionality.
Radiopharma Leadership & Manufacturing PlansOwning a leading radiopharma unit and building Kazusa manufacturing creates vertical capability to commercialize RI diagnostics/therapeutics. In‑house production can accelerate regulatory/commercial transitions, capture manufacturing margins, and form a durable competitive advantage in a specialized, high‑barrier segment.
Bears Say
Negative Cash GenerationTTM negative operating and free cash flow mark a clear reversal from prior cash‑positive periods. Sustained cash burn increases reliance on milestone/upfront receipts or external financing, raises execution risk for R&D and capex plans, and amplifies funding sensitivity if large partner payments slip beyond the 2–6 month horizon.
Return To Losses / Margin PressureDespite strong top‑line growth, margins swung negative and ROE turned adverse, indicating costs and investment outpaced revenue realization. Persistent negative profitability undermines self‑funding of growth, may pressure strategic choices, and means long‑term value depends on timing of partner milestones and eventual commercialization revenue.
Revenue Timing & Partner VisibilityBusiness model dependence on large, lumpy upfronts concentrates revenue risk: delayed out‑licensing (myostatin) and opaque partner disclosures create material timing uncertainty for cash inflows. This elevates execution risk for funding planned R&D, manufacturing and launches, making near‑term financial outcomes contingent on partner decisions.
Peptidream News
4587 FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was ¥985.10 and its highest was ¥1818.50 in the past 12 months.
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is ¥130.02B.
When is Peptidream Inc.’s upcoming earnings report date?
Peptidream Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 62 days.
How were Peptidream Inc.’s earnings last quarter?
Peptidream Inc. released its earnings results on May 13, 2026. The company reported -¥6.62 earnings per share for the quarter, beating the consensus estimate of -¥8.05 by ¥1.43.
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Overvalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate is -3.19.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Peptidream Inc. reported an EPS of -¥6.62 in its last earnings report, beating expectations of -¥8.05. Following the earnings report the stock price went down -0.178%.
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in JP:4587
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.
4587 Company Deck
4587 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial operational and pipeline progress — notably strong clinical momentum (6 programs entering clinic in 2025, 13 total clinical programs), late-stage radiopharmaceutical programs with NDA timelines, IND acceptances and a healthy cash balance (JPY 28.6 billion). At the same time, key revenue drivers were delayed (notably the myostatin out‑licensing), R&D and headcount-driven costs are increasing (R&D +28% year-over-year; headcount +6.4%), and several high-value deals remain timing-uncertain. Overall, the company appears to be transitioning from a discovery-focused model to a discovery-and-development company with meaningful upside from pipeline advances, but near-term financial performance depends on timing of large upfront deals and execution of planned manufacturing expansions.View all JP:4587 earnings summaries4587 Stock 12 Month Forecast
Average Price Target
¥1,600.00
▼(-4.13% Downside)
Technical Analysis
Options Prices
Currently, No data available
---